Profile data is unavailable for this security.
About the company
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
- Revenue in HKD (TTM)2.02bn
- Net income in HKD-790.79m
- Incorporated2019
- Employees2.82k
- LocationAkeso IncNo.6 Shennong RoadHuoju Development ZoneZhongshan 528437ChinaCHN
- Phone+86 76 089873998
- Fax+86 76 089873900
- Websitehttps://www.akesobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genscript Biotech Corp | 7.86bn | -1.38bn | 21.67bn | 7.28k | -- | 2.29 | -- | 2.76 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,655.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 2.02bn | -250.33m | 37.44bn | 1.54k | -- | 10.85 | -- | 18.55 | -1.11 | -1.11 | 9.12 | 15.49 | 0.5869 | 9.46 | 167.74 | 1,426,591.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 18.41bn | 2.83bn | 59.83bn | 12.44k | 21.99 | 1.37 | 12.33 | 3.25 | 0.6548 | 0.6548 | 4.28 | 10.53 | 0.3163 | 5.35 | 2.98 | 1,444,847.00 | 5.57 | 8.28 | 6.85 | 10.25 | 38.66 | 43.25 | 17.60 | 27.46 | 2.62 | -- | 0.0928 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Akeso Inc | 2.02bn | -790.79m | 64.80bn | 2.82k | -- | 11.12 | -- | 32.15 | -0.9414 | -0.9414 | 2.40 | 6.49 | 0.1925 | 0.3707 | 5.27 | 725,516.80 | -8.18 | -11.59 | -9.19 | -13.87 | 92.21 | -- | -42.50 | -42.49 | 4.43 | -5.49 | 0.3922 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
Data as of Nov 26 2024. Currency figures normalised to Akeso Inc's reporting currency: Hong Kong Dollar HKD
17.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Green Court Capital Management Ltd.as of 25 Sep 2024 | 43.14m | 4.81% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 33.44m | 3.73% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 25.09m | 2.80% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 9.96m | 1.11% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 9.19m | 1.02% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 8.73m | 0.97% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 8.43m | 0.94% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Sep 2024 | 7.41m | 0.83% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 6.33m | 0.71% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 6.27m | 0.70% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
